ondelopran
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Nov 1, 2008 (NCT00804570)
Timeline
Indications
Studied for
Mechanism of action
- Opioid receptors; mu/kappa/deltaANTAGONIST
Opioid receptors; mu/kappa/delta antagonist
Chemistry & pharmacology
Loading structure…
SMILES
NC(=O)c1ccc(Oc2ccc(CNCCC3CCOCC3)cc2F)nc1- Mol. weight
- 373.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2103878 ↗
Also known as
- ly2196044
- ly2196044
- ly-2196044
- ly-2196044
- odelepran
- odelepran
- ondelopran
- ondelopran
- ondelopran
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03663374 | Phase 3 | Nov 18, 2014 | R-Pharm, Synergy Research |
| NCT00804570 | Phase 2 | Nov 1, 2008 | Eli Lilly |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 1 | 1 | 1 | 2008 |
| R-Pharm | For profit | 1 | 1 | 1 | 2014 |
| Synergy Research | For profit | 1 | 0 | 1 | 2014 |
3 organizations
Page 1 / 1